Compare AZTA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZTA | RAPP |
|---|---|---|
| Founded | 1978 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2024 |
| Metric | AZTA | RAPP |
|---|---|---|
| Price | $20.15 | $27.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $42.60 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 826.8K | 292.7K |
| Earning Date | 05-06-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $593,821,000.00 | N/A |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.22 | $7.73 |
| 52 Week High | $41.73 | $42.27 |
| Indicator | AZTA | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 21.98 | 45.42 |
| Support Level | N/A | $26.67 |
| Resistance Level | $32.18 | $29.51 |
| Average True Range (ATR) | 1.15 | 1.88 |
| MACD | -0.03 | -0.31 |
| Stochastic Oscillator | 0.08 | 27.77 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.